



EXPRESS MAIL LABEL NO. : *EV 33399 7777 48*

**COMMUNICATION
Regarding Deceased Inventor**

Lodewijk A. Sandkuijl

Attorney Docket No.	UCAL-154CIP5
Confirmation No.	7721
First Named Inventor	FREIMER, NELSON B.
Application Number	10/629,313
Filing Date	July 28, 2003
Group Art Unit	1653
Examiner Name	Not Yet Assigned
Title:	"METHODS OF COMPOSITIONS FOR DIAGNOSING AND TREATING CHROMOSOME-18p RELATED DISORDERS"

Dear Sir:

As set forth in 37 CFR §1.42, in case of the death of an inventor, the legal representative of the deceased inventor may make the necessary oath or declaration, and apply for and obtain the patent.

In the instant case, the inventor Lodewijk A. Sandkuijl is deceased. The legal representative of the deceased inventor is Ms. L. Sandkuijl-Schakenbos. The address of the legal representative for of Lodewijk A. Sandkuijl is as follows:

Ms. L. Sandkuijl-Schakenbos

Voorstraat 27 a

2611 JK Delft, The Netherlands

A declaration signed by **Ms. L. Sandkuijl-Schakenbos** the legal representative of **Lodewijk A. Sandkuijl**.

The Commissioner is hereby authorized to charge and fees associated with this communication, including any necessary fees for extensions of time, or credit any overpayment to Deposit Account No. 50-0815, order number UCAL-154CIP5.

Respectfully submitted,
BOZICEVIC, FIELD & FRANCIS LLP

Date: *April 6, 2004*

By: *Carol L. Francis*

Carol L. Francis
Registration No. 36,513

BOZICEVIC, FIELD & FRANCIS LLP
200 Middlefield Road, Suite 200
Menlo Park, CA 94025
Telephone: (650) 327-3400
Facsimile: (650) 327-3231

**DECLARATION (37 CFR 1.63) FOR UTILITY OR DESIGN APPLICATION USING AN
APPLICATION DATA SHEET (37 CFR 1.76) UCAL-154CIP5**

Title of Invention	METHODS OF COMPOSITIONS FOR DIAGNOSING AND TREATING CHROMOSOME-18P RELATED DISORDERS
--------------------	--

As the below named inventor(s), I/we declare that:

This declaration is directed to:

- ☐ The attached application, or
☒ Application No. 10/629,313 filed on July 28, 2003,
☐ as amended on _____ (if applicable);

I/we believe that I/we am/are the original and first inventor(s) of the subject matter which is claimed and for which a patent is sought;

I/we have reviewed and understand the contents of the above-identified application, including the claims, as amended by any amendment specifically referred to above;

I/we acknowledge the duty to disclose to the United States Patent and Trademark Office all information known to me/us to be material to patentability as defined in 37 CFR 1.56, including material information which became available between the filing date of the prior application and the national or PCT International filing date of the continuation-in-part application, if applicable; and.

All statements made herein of my/our own knowledge are true, all statements made herein on information and belief are believed to be true, and further that these statements were made with the knowledge that willful false statements and the like are punishable by fine or imprisonment, or both, under 18 U.S.C. 1001, and may jeopardize the validity of the application or any patent issuing thereon.

As a named inventor I hereby appoint Practitioners at Customer Number 24353 as my/our attorney(s) or agent(s) to prosecute the application identified above, and to transact all business in the United States Patent and Trademark Office connected therewith

FULL NAME OF INVENTOR(S)

Inventor one: NELSON B. FREIMERSignature: [Signature]Citizen of: USAInventor two: VICTOR J. REUS

Signature: _____

Citizen of: _____

Inventor three: SUSAN K. SERVICE

Signature: _____

Citizen of: _____

Inventor four: LYNNE ALLISON MCINNES

Signature: _____

Citizen of: _____

☒ Additional inventors are being named on 1 additional form(s) attached hereto.

PAGE 1 OF 2



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

**DECLARATION (37 CFR 1.63) FOR UTILITY OR DESIGN APPLICATION USING AN
APPLICATION DATA SHEET (37 CFR 1.76) UCAL-154CIP5**

Title of Invention	METHODS OF COMPOSITIONS FOR DIAGNOSING AND TREATING CHROMOSOME-18P RELATED DISORDERS
--------------------	--

As the below named inventor(s), I/we declare that:

This declaration is directed to:

- ☐ The attached application, or
☒ Application No. 10/629,313 filed on July 28, 2003,
☐ as amended on _____ (if applicable);

I/we believe that I/we am/are the original and first inventor(s) of the subject matter which is claimed and for which a patent is sought;

I/we have reviewed and understand the contents of the above-identified application, including the claims, as amended by any amendment specifically referred to above;

I/we acknowledge the duty to disclose to the United States Patent and Trademark Office all information known to me/us to be material to patentability as defined in 37 CFR 1.56, including material information which became available between the filing date of the prior application and the national or PCT International filing date of the continuation-in-part application, if applicable; and.

All statements made herein of my/our own knowledge are true, all statements made herein on information and belief are believed to be true, and further that these statements were made with the knowledge that willful false statements and the like are punishable by fine or imprisonment, or both, under 18 U.S.C. 1001, and may jeopardize the validity of the application or any patent issuing thereon.

As a named inventor I hereby appoint Practitioners at Customer Number 24353 as my/our attorney(s) or agent(s) to prosecute the application identified above, and to transact all business in the United States Patent and Trademark Office connected therewith

FULL NAME OF INVENTOR(S)

Inventor one: NELSON B. FREIMER

Signature: _____ Citizen of: _____

Inventor two: VICTOR I. REUS

Signature: *Victor I. Reus* Citizen of: USA

Inventor three: SUSAN K. SERVICE

Signature: _____ Citizen of: _____


Inventor four: LYNNE ALLISON MCINNES

Signature: _____ Citizen of: _____

☒ Additional inventors are being named on 1 additional form(s) attached hereto.

PAGE 1 OF 2

Burden Hour Statement: This collection of information is required by 35 U.S.C. 115 and 37 CFR 1.63. The information is used by the public to file (and the PTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This form is estimated to take 1 minute to complete. This time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

PTO/SB/01a (10-01)

Approved for use through 10/31/2002. OMB 0651-0032

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

**DECLARATION (37 CFR 1.63) FOR UTILITY OR DESIGN APPLICATION USING AN
APPLICATION DATA SHEET (37 CFR 1.76) UCAL-154CIP5**

Title of Invention METHODS OF COMPOSITIONS FOR DIAGNOSING AND TREATING CHROMOSOME-18P RELATED DISORDERS

As the below named inventor(s), I/we declare that:

This declaration is directed to:

- ☐ The attached application, or
☒ Application No. 10/629,313 filed on July 28, 2003,
☐ as amended on _____ (if applicable);

I/we believe that I/we am/are the original and first inventor(s) of the subject matter which is claimed and for which a patent is sought;

I/we have reviewed and understand the contents of the above-identified application, including the claims, as amended by any amendment specifically referred to above;

I/we acknowledge the duty to disclose to the United States Patent and Trademark Office all information known to me/us to be material to patentability as defined in 37 CFR 1.56, including material information which became available between the filing date of the prior application and the national or PCT International filing date of the continuation-in-part application, if applicable; and.

All statements made herein of my/our own knowledge are true, all statements made herein on information and belief are believed to be true, and further that these statements were made with the knowledge that willful false statements and the like are punishable by fine or imprisonment, or both, under 18 U.S.C. 1001, and may jeopardize the validity of the application or any patent issuing thereon.

As a named inventor I hereby appoint Practitioners at Customer Number 24353 as my/our attorney(s) or agent(s) to prosecute the application identified above, and to transact all business in the United States Patent and Trademark Office connected therewith

FULL NAME OF INVENTOR(S)

Inventor one: NELSON B. FREIMER

Signature: _____ Citizen of: _____

Inventor two: VICTOR I. REUS

Signature: _____ Citizen of: _____

Inventor three: SUSAN K. SERVICE

Signature: Susan K. Service Citizen of: USA

Inventor four: LYNNE ALLISON MCINNES

Signature: _____ Citizen of: _____

☒ Additional inventors are being named on 1 additional form(s) attached hereto.

PAGE 1 OF 2

Burden Hour Statement: This collection of information is required by 35 U.S.C. 115 and 37 CFR 1.63. The information is used by the public to file (and the PTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This form is estimated to take 1 minute to complete. This time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

MAR-02-04 TUE 04:21 PM BOZICEVIC

FAX NO. 650 327 3231

P. 03



PTO/USPO (10-01)

Approved for use through 10/1/02, OMB 0351-0032

U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

DECLARATION (37 CFR 1.63) FOR UTILITY OR DESIGN APPLICATION USING AN APPLICATION DATA SHEET (37 CFR 1.76) UCAI-154CIP5

Title of Invention: METHODS OF COMPOSITIONS FOR DIAGNOSING AND TREATING CHROMOSOMAL-REPAIR RELATED DISORDERS

As the below named inventor(s), I/we declare that:

This declaration is directed to:

- ☐ The attached application, or
☒ Application No. 10/029,213, filed on July 28, 2003,
☐ as amended on _____ (if applicable):

I/we believe that I/we am/are the original and first inventor(s) of the subject matter which is claimed and for which a patent is sought;

I/we have reviewed and understand the contents of the above-identified application, including the claims, as amended by any amendment specifically referred to above;

I/we acknowledge the duty to disclose to the United States Patent and Trademark Office all information known to me/us to be material to patentability as defined in 37 CFR 1.56, including material information which became available between the filing date of the prior application and the national or PCT international filing date of the continuation-in-part application, if applicable; and,

All statements made herein of my/our own knowledge are true, all statements made herein on information and belief are believed to be true, and further that these statements were made with the knowledge that willful false statements and the like are punishable by fine or imprisonment, or both, under 18 U.S.C. 1001, and may jeopardize the validity of the application or any patent issuing thereon.

As a named inventor I hereby appoint Practitioners at Customer Number **24353** as my/our attorney(s) or agent(s) to prosecute the application identified above, and to transact all business in the United States Patent and Trademark Office connected therewith.

FULL NAME OF INVENTOR(S)

Inventor one: NELSON B. FREIMER

Signature: _____ Citizen of: _____

Inventor two: VICTOR I. REUS

Signature: _____ Citizen of: _____

Inventor three: SUSAN K. SERVICE

Signature: _____ Citizen of: _____


Inventor four: LYNNE ALISON MCINNES

Signature: *[Signature]* Citizen of: 03/03/04

☒ Additional inventors are being named on 1 additional page(s) attached hereto.

PAGE 1 OF 2

Burden Hour Statement: This collection of information is required by 35 U.S.C. 116 and 37 C.F.R. 1.63. The information is used by the office to file and process an application. Confidentiality is governed by 35 U.S.C. 122 and 37 C.F.R. 1.14. This form is estimated to take 1 minute to complete. This form will only be provided upon the request of the individual case. Any comments on the accuracy of this form are required to be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND THIS OR COMPLETED FORMS TO THIS ADDRESS. Send to: Assistant Commissioner for Patents, Washington, DC 20231.

**DECLARATION (37 CFR 1.63) FOR UTILITY OR DESIGN APPLICATION USING AN
APPLICATION DATA SHEET (37 CFR 1.76) UCAL-154CIP5**

Title of Invention	METHODS OF COMPOSITIONS FOR DIAGNOSING AND TREATING CHROMOSOME-18P RELATED DISORDERS
---------------------------	---

As the below named inventor(s), I/we declare that:

This declaration is directed to:

- ☐ The attached application, or
☒ Application No. **10/629,313** filed on **July 28, 2003**,
☐ as amended on _____ (if applicable);

I/we believe that I/we am/are the original and first inventor(s) of the subject matter which is claimed and for which a patent is sought;

I/we have reviewed and understand the contents of the above-identified application, including the claims, as amended by any amendment specifically referred to above;

I/we acknowledge the duty to disclose to the United States Patent and Trademark Office all information known to me/us to be material to patentability as defined in 37 CFR 1.56, including material information which became available between the filing date of the prior application and the national or PCT International filing date of the continuation-in-part application, if applicable; and.

All statements made herein of my/our own knowledge are true, all statements made herein on information and belief are believed to be true, and further that these statements were made with the knowledge that willful false statements and the like are punishable by fine or imprisonment, or both, under 18 U.S.C. 1001, and may jeopardize the validity of the application or any patent issuing thereon.

As a named inventor I hereby appoint Practitioners at Customer Number **24353** as my/our attorney(s) or agent(s) to prosecute the application identified above, and to transact all business in the United States Patent and Trademark Office connected therewith

FULL NAME OF INVENTOR(S)

Inventor one: **NELSON B. FREIMER**

Signature: _____ Citizen of: _____

Inventor two: **VICTOR I. REUS**

Signature: _____ Citizen of: _____

Inventor three: **SUSAN K. SERVICE**


Signature: _____ Citizen of: _____

Inventor four: **LYNNE ALISON MCINNES**

Signature: _____ Citizen of: _____

☒ Additional inventors are being named on 1 additional form(s) attached hereto.

PAGE 1 OF 2

**DECLARATION (37 CFR 1.63) FOR UTILITY OR DESIGN APPLICATION USING AN
APPLICATION DATA SHEET (37 CFR 1.76) UCAL-154CIP5**

Title of Invention	METHODS OF COMPOSITIONS FOR DIAGNOSING AND TREATING CHROMOSOME-18P RELATED DISORDERS
--------------------	--

FULL NAME OF INVENTOR(S)

Inventor five: HONG CHEN

Signature:

Citizen of:

USAInventor six: PEDRO LEON

Signature: _____

Citizen of: _____

Inventor seven: LODEWIJK SANDKUIJL (deceased)Citizen of: The Netherlands

Signed By: _____

Ms. Lineke Sandkuijl-Schakenbos; Legal Representative

Burden Hour Statement: This collection of information is required by 35 U.S.C. 115 and 37 CFR 1.63. The information is used by the public to file (and the PTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This form is estimated to take 1 minute to complete. This time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

**DECLARATION (37 CFR 1.63) FOR UTILITY OR DESIGN APPLICATION USING AN
APPLICATION DATA SHEET (37 CFR 1.76) UCAL-154CIP5**

Title of Invention	METHODS OF COMPOSITIONS FOR DIAGNOSING AND TREATING CHROMOSOME-18P RELATED DISORDERS
---------------------------	---

As the below named inventor(s), I/we declare that:

This declaration is directed to:

- ☐ The attached application, or
☒ Application No. **10/629,313** filed on **July 28, 2003**,
☐ as amended on _____ (if applicable);

I/we believe that I/we am/are the original and first inventor(s) of the subject matter which is claimed and for which a patent is sought;

I/we have reviewed and understand the contents of the above-identified application, including the claims, as amended by any amendment specifically referred to above;

I/we acknowledge the duty to disclose to the United States Patent and Trademark Office all information known to me/us to be material to patentability as defined in 37 CFR 1.56, including material information which became available between the filing date of the prior application and the national or PCT International filing date of the continuation-in-part application, if applicable; and.

All statements made herein of my/our own knowledge are true, all statements made herein on information and belief are believed to be true, and further that these statements were made with the knowledge that willful false statements and the like are punishable by fine or imprisonment, or both, under 18 U.S.C. 1001, and may jeopardize the validity of the application or any patent issuing thereon.

As a named inventor I hereby appoint Practitioners at Customer Number **24353** as my/our attorney(s) or agent(s) to prosecute the application identified above, and to transact all business in the United States Patent and Trademark Office connected therewith**FULL NAME OF INVENTOR(S)**Inventor one: **NELSON B. FREIMER**

Signature: _____ Citizen of: _____

Inventor two: **VICTOR I. REUS**

Signature: _____ Citizen of: _____


Inventor three: **SUSAN K. SERVICE**

Signature: _____ Citizen of: _____

Inventor four: **LYNNE ALISON MCINNES**

Signature: _____ Citizen of: _____

☒ Additional inventors are being named on 1 additional form(s) attached hereto.**PAGE 1 OF 2**

DECLARATION (37 CFR 1.63) FOR UTILITY OR DESIGN APPLICATION USING AN APPLICATION DATA SHEET (37 CFR 1.76) UCAL-154CIP5	
Title of Invention	METHODS OF COMPOSITIONS FOR DIAGNOSING AND TREATING CHROMOSOME-18P RELATED DISORDERS
FULL NAME OF INVENTOR(S)	
Inventor five: HONG CHEN	
Signature: _____ Citizen of: _____	
Inventor six: PEDRO LEON	
Signature:  Citizen of: <u>Costa Rica</u>	
Inventor seven: LODEWIJK SANDKUIJL (deceased) Citizen of: <u>The Netherlands</u>	
Signed By: _____ Ms. L. Sandkuijl-Schakenbos; Legal Representative	

Burden Hour Statement: This collection of information is required by 35 U.S.C. 115 and 37 CFR 1.63. The information is used by the public to file (and the PTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This form is estimated to take 1 minute to complete. This time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

**DECLARATION (37 CFR 1.63) FOR UTILITY OR DESIGN APPLICATION USING AN
APPLICATION DATA SHEET (37 CFR 1.76) UCAL-154CIP5**

Title of Invention	METHODS OF COMPOSITIONS FOR DIAGNOSING AND TREATING CHROMOSOME-18P RELATED DISORDERS
---------------------------	---

A legal representative of Lodewijk A. Sandkuijl a named inventor, I declare that:

This declaration is directed to:

- ☐ The attached application, or
☒ Application No. 10/629,313 filed on July 28, 2003,
☐ as amended on _____ (if applicable);

I, **L. Sandkuijl-Schakenbos** am the legal representative for Lodewijk A. Sandkuijl, and I believe that Lodewijk A. Sandkuijl, with the other inventors named below, are the original and first inventors of the subject matter which is claimed and for which a patent is sought;

I have reviewed and understand the contents of the above-identified application, including the claims, as amended by any amendment specifically referred to above;

I acknowledge the duty to disclose to the United States Patent and Trademark Office all information known to me/us to be material to patentability as defined in 37 CFR 1.56, including material information which became available between the filing date of the prior application and the national or PCT International filing date of the continuation-in-part application, if applicable; and.

All statements made herein of my own knowledge are true, all statements made herein on information and belief are believed to be true, and further that these statements were made with the knowledge that willful false statements and the like are punishable by fine or imprisonment, or both, under 18 U.S.C. 1001, and may jeopardize the validity of the application or any patent issuing thereon.

As legal representative of Lodewijk A. Sandkuijl, a named inventor, I hereby appoint Practitioners at Customer Number 24353 as my attorney(s) or agent(s) to prosecute the application identified above, and to transact all business in the United States Patent and Trademark Office connected therewith

FULL NAME OF INVENTOR(S)

Inventor one: NELSON B. FREIMER

Inventor two: VICTOR I. REUS

Inventor three: SUSAN K. SERVICE

Inventor four: LYNNE ALISON MCINNES

☒ Additional inventors are being named on 1 additional form(s) attached hereto.

PAGE 1 OF 2

Burden Hour Statement: This collection of information is required by 35 U.S.C. 115 and 37 CFR 1.63. The information is used by the public to file (and the PTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This form is estimated to take 1 minute to complete. This time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

DECLARATION (37 CFR 1.63) FOR UTILITY OR DESIGN APPLICATION USING AN APPLICATION DATA SHEET (37 CFR 1.76)		UCAL-154CIP5
Title of Invention	METHODS OF COMPOSITIONS FOR DIAGNOSING AND TREATING CHROMOSOME-18P RELATED DISORDERS	
FULL NAME OF INVENTOR(S)		
Inventor five: HONG CHEN		
Inventor six: PEDRO LEON		
Inventor seven: LODEWIJK A. SANDKUIJL (deceased) Citizen of: The Netherlands		
Signed By: <u><i>L. Sandkuijl-Schakenbos</i></u> Citizen of: The Netherlands <i>March 4, 2004</i> Ms. L. Sandkuijl-Schakenbos as Legal Representative for Lodewijk A. Sandkuijl Voorstraat 27 a 2611 JK Delft, The Netherlands		

Burden Hour Statement: This collection of information is required by 35 U.S.C. 115 and 37 CFR 1.63. The information is used by the public to file (and the PTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This form is estimated to take 1 minute to complete. This time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.